SOPHiA GENETICS SA — 2023 Form 20-F Summary
Reporting period: Fiscal year ended December 31, 2023. This is an annual report, not a standalone fourth-quarter filing; the filing does not provide a clear standalone Q4 financial result. Financial statements are in U.S. dollars and prepared under IFRS Accounting Standards as issued by the IASB. The company is a Swiss healthcare software and genomics analytics provider, listed on Nasdaq as SOPH.
Business context
SOPHiA GENETICS operates the cloud-based SOPHiA DDM platform for genomics and multimodal healthcare data analysis, serving clinical and biopharma customers. At year-end, it reported more than 770 total customers, 450 core genomics customers, over 1.5 million genomic profiles analyzed, and operations in 68 countries. The U.S. products are labeled for research use only; the company also markets CE-IVD products in Europe.
Financial and operating metrics
| Metric | 2023 | 2022 | Change |
|---|---|---|---|
| Revenue | $62.4 million | $47.6 million | +31% |
| Gross profit / margin | $42.9 million / 69% | $31.3 million / 66% | Margin +3 percentage points |
| Operating loss | $74.8 million | $87.8 million | Loss narrowed $13.0 million |
| Net loss | $79.0 million | $87.4 million | Loss narrowed $8.5 million |
| Net loss per share | $1.22 | $1.36 | Improved |
| Cash used in operating activities | $48.6 million | $70.1 million | Use decreased $21.5 million |
| Cash and cash equivalents at year-end | $123.3 million | $161.3 million | Down $38.1 million |
SOPHiA DDM Platform revenue was $60.9 million, up 33%; workflow equipment and services revenue was $1.5 million, down 22%. Chargeable platform analyses rose 20% to 317,062. Net dollar retention for dry-lab and bundle customers was 130%, versus 102% in 2022. The filing attributes growth principally to higher customer usage, new customers, oncology applications and a $3.8 million increase in biopharma revenue.
Research and development expense was $37.0 million; selling and marketing was $28.4 million; and general and administrative expense was $53.3 million. Interest income, net, increased to $4.0 million. Foreign exchange and other losses increased to $7.6 million, primarily from unrealized losses on intercompany receivables.
Liquidity, debt and commitments
The company reported $123.3 million in cash and cash equivalents, no term deposits and no outstanding borrowings at December 31, 2023. Lease liabilities totaled $18.6 million. Management said existing cash should cover working capital and capital expenditure needs for at least 12 months; the company nevertheless expects continuing losses and may need additional capital. An at-the-market program allows sales of up to $50 million of shares; no shares were sold under it in 2023. A Microsoft agreement commits the company to approximately $69.4 million of computing and hosting costs through October 2027.
Outlook, risks and notable items
- Management expects continued net losses while investing in research and development, commercial expansion, customer and collaborator relationships, and regulatory clearances. It has expressed a goal of becoming cash-flow positive in the next two or more years, but cautions this may not occur on that timeline or at all.
- Management expects near-term gross margin pressure from higher cloud computing and storage capacity costs, while citing scale and cost initiatives as potential longer-term improvements.
- Key risks include uncertain adoption and reimbursement, competition and rapid technology change, regulatory requirements for U.S. diagnostic products and evolving oversight of laboratory-developed tests, data privacy and cybersecurity, dependence on cloud and other third parties, and continued reliance on external capital.
- Currency movements were a notable earnings item: 2023 foreign exchange and other losses were $7.6 million, largely unrealized. No material cybersecurity incident was identified in 2023, and the company reported no material subsequent events or litigation expected to have a material adverse effect.
- Management assessed disclosure controls and internal control over financial reporting as effective. The auditor did not provide an internal-control attestation because the company is an emerging growth company. The filing reports an unqualified audit opinion on the IFRS financial statements.
Investor verification priorities
- Review audited statements and cash-flow details, including whether operating cash use, share-based compensation and working-capital movements support the stated liquidity outlook.
- Track cash runway against continued losses, the $69.4 million Microsoft commitment, lease obligations and any use of the $50 million ATM program.
- Assess the durability of revenue growth and 130% net dollar retention, including customer utilization, biopharma revenue and the decline in COVID-19-related activity.
- Monitor gross margin and cloud costs, as well as the extent to which reported foreign-exchange losses recur or become cash losses.
- Verify progress on regulatory clearances, reimbursement, privacy compliance and the potential impact of changes to U.S. LDT oversight.
- Consider dilution and governance factors, including equity awards, treasury-share activity and the company’s Swiss-law and foreign-private-issuer framework.